In 1995 S. Mazzari, R. Canella, G. Marcolongo and A. Leon published an abstract were they demonstrated that pure PEA, given in a dose of (0.03-10 mg/kg) per os to rats could inhibit mast cell activation and reduce inflammation.
PEA was biologically more active than a NSAID given in the rat model the authors used. PEA (code name at that time for the pure PEA was LG 2110/1) in a dose of 0.03 to 10 mg/kg, diminished plasma extravasation induced in the mouse ear pinna by local injection of substance P (SP) and, in contrast to NSAIDs, reduced the passive cutaneous anaphylaxis reaction.
In the abstract the authors refered to the ALIA concept:
The present results not only strenghten the Autacoid Local
Inflammation Antagonism (ALIA)-like role of N-
(hydroxyethyl)hexadecanamide but also
propose that LG 2110/1 and its derivatives (ALIAMIDES) may
provide a novel therapeutic strategy for the management of
inflammatory disease states, including nerve inflammation and
Source: (full paper) N-(2-HYDROXYETHYL)HEXADECANAMIDE REDUCES EDEMA FORMATION AND HYPERALGESIA BY DOWN-MODULATING MAST CELL ACTIVATION in: Eur J Pharmacol. 1996 Apr 11;300(3):227-36.